Kamini Rajaratnam and Yu-Tao Xiang and Adarsh Tripathi and Helen F K Chiu and Tian-Mei Si and Kok-Yoon Chee and Ajit Avasthi and Sandeep Grover and Mian-Yoon Chong and Hironori Kuga and Shigenobu Kanba and Yan-Ling He and Min-Soo Lee and Shu-Yu Yang and Pichet Udomratn and Roy A Kallivayalil and Andi J Tanra and Margarita M Maramis and Winston W Shen and Norman Sartorius and Ee-Heok Kua and Chay-Hoon Tan and Rathi Mahendran and Naotaka Shinfuku and Min Yi Sum and Ross J Baldessarini and Kang Sim (2017) Clinical Use of Mood Stabilizers With Antidepressants in Asia Report From the Research on Asian Psychotropic Prescription Patterns for Antidepressants (REAP-AD) Projects in 2004 and 2013. Journal of Clinical Psychopharmacology, 37 (2). ISSN ISSN:0271-0749E-ISSN:1533-712X

	Text (Artikel) 15. Clinical Use of Mood.pdf Download (2MB)
	Text (Kualitas Karil & Kesesuaian Bidang Ilmu) C-15.pdf Download (79kB)
	Text (Turnitin) 15. Clinical Use of Mood Stabilizers With.pdf Download (1MB)

Abstract

Abstract Objective: As most reports concerning treatment with combinations of mood stabilizer (MS) with antidepressant (AD) drugs are based in the West, we surveyed characteristics of such cotreatment in 42 sites caring for the mentally ill in 10 Asian countries. Methods: This cross-sectional, pharmacoepidemiologic study used 2004 and 2013 data from the REAP-AD (Research Study on Asian Psychotropic Prescription Patterns for Antidepressants) to evaluate the rates and doses of MSs given with ADs and associated factors in 4164 psychiatric patients, using standard bivariate methods followed by multivariable logistic regression modeling. Results: Use of MS + AD increased by 104% (5.5% to 11.2%) between 2004 and 2013 and was much more associated with diagnosis of bipolar disorder than major depression or anxiety disorder, as well as with hospitalization > outpatient care, psychiatric > general-medical programs, and young age (all P < 0.001), but not with country, sex, or AD dose. Conclusions: The findings provide a broad picture of contemporary use of MSs with ADs in Asia, support predictions that such treatment increased in recent years, and was associated with diagnosis of bipolar disorder, treatment in inpatient and psychiatric settings, and younger age.

Actions (login required)

View Item